抢先式同期胰肾联合移植对患者具有生存获益
基于OPTN/UNOS数据库2000至2017年9690例同期胰肾联合移植受者的回顾性分析,采用倾向性评分分析减少偏倚;其中1796例(19%)为抢先式移植。抢先式组10年受者生存率显著优于非抢先式组(78.9% vs 71.8%),透析及透析≥12个月是受者生存的独立危险因素;抢先式移植也与肾脏移植物生存显著更优相关,而胰腺移植物生存和术后手术并发症两组无差异。
要点
- 抢先式同期胰肾联合移植受者10年生存率显著优于非抢先式(78.9% vs 71.8%)。
- 移植时透析是受者生存的独立危险因素(HR 1.66,95%CI 1.32-2.09),透析≥12个月尤甚。
- 抢先式移植肾脏移植物生存显著更优(删失死亡 84.3% vs 75.4%),胰腺移植物生存与手术并发症无差异。
核心结论
- 抢先式同期胰肾联合移植与非抢先式相比,受者生存和肾脏移植物生存显著更优,胰腺移植物生存和术后手术并发症无差异。
- 结果支持胰腺移植早期转诊的相关性以及胰腺分配优先在降低同期胰肾联合移植后患者死亡率中的重要性。
研究设计与样本
- 回顾性分析OPTN/UNOS数据库2000至2017年9690例同期胰肾联合移植受者,采用倾向性评分分析以减少偏倚。
主要发现
- 9690例受者中1796例(19%)为抢先式移植。
- 10年受者生存率抢先式组78.9% vs 非抢先式组71.8%,抢先式组显著更优。
- 移植时透析是受者生存的独立显著危险因素(HR 1.66,95%CI 1.32-2.09),透析持续时间≥12个月时尤甚。
- 肾脏移植物生存(删失死亡)抢先式组84.3% vs 透析组75.4%,抢先式组显著更优;估计半衰期分别为38.57(38.33-38.81)年 vs 22.35(22.17-22.53)年。
- 胰腺移植物生存和移植术后手术并发症两组间均无差异。
临床怎么用
- 作者认为结果支持胰腺移植早期转诊的相关性以及胰腺分配优先在降低同期胰肾联合移植后患者死亡率中的重要性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Several organ allocation protocols give priority to wait-listed simultaneous kidney-pancreas (SPK) transplant recipients to mitigate the higher cardiovascular risk of patients with diabetes mellitus on dialysis. The available information regarding the impact of preemptive simultaneous kidney-pancreas transplantation on recipient and graft outcomes is nonetheless controversial. To help resolve this, we explored the influence of preemptive simultaneous kidney-pancreas transplants on patient and graft survival through a retrospective analysis of the OPTN/UNOS database, encompassing 9690 simultaneous transplant recipients between 2000 and 2017. Statistical analysis was performed applying a propensity score analysis to minimize bias. Of these patients, 1796 (19%) were transplanted preemptively. At ten years, recipient survival was significantly superior in the preemptive group when compared to the non-preemptive group (78.9% vs 71.8%). Dialysis at simultaneous kidney-pancreas transplantation was an independent significant risk for patient survival (hazard ratio 1.66 [95% confidence interval 1.32-2.09]), especially if the dialysis duration was 12 months or longer. Preemptive transplantation was also associated with significant superior kidney graft survival compared to those on dialysis (death-censored: 84.3% vs 75.4%, respectively; estimated half-life of 38.57 [38.33 -38.81] vs 22.35 [22.17 - 22.53] years, respectively). No differences were observed between both groups neither for pancreas graft survival nor for post-transplant surgical complications. Thus, our results sustain the relevance of early referral for pancreas transplantation and the importance of pancreas allocation priority in reducing patient mortality after simultaneous kidney-pancreas transplantation.
引用
- Montagud-Marrahi E, Cuadrado-Payán E, Hermida E, et al. Preemptive simultaneous pancreas kidney transplantation has survival benefit to patients. Kidney Int. 2022. PMID: 35644282. doi:10.1016/j.kint.2022.04.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。